RFK Jr. Blamed by HHS Staff for Misinformation That Sparked CDC Attack
Kennedy's words and actions 'contributed to the harassment and violence' experienced by US Centers for Disease Control and Prevention staff and directly led to the Aug. 8 attack on the agency, according to a letter signed by more than 750 employees and sent to the secretary and members of Congress on Wednesday. He was 'complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information,' it read.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Mizuho Raises Boston Scientific (BSX) Price Target as Robotics and Devices Drive Growth
Boston Scientific Corporation (NYSE:BSX) ranks among the . Mizuho kept its Outperform rating on Boston Scientific Corporation (NYSE:BSX), and increased its price target for the medical device maker from $130 to $140 on July 24. The firm reported that the global recall of the ACURATE transcatheter aortic valve replacement (TAVR) system in the second half of the year was expected to be compensated by solid performance in Boston Scientific's FARAPULSE and WATCHMAN product lines. While Boston Scientific Corporation (NYSE:BSX) has no plans to re-engineer the ACURATE valve, putting it 'at square one in the TAVR space,' the company is still on track to acquire clearances for FARAPULSE in China and Japan before the end of the year, according to Mizuho's research. Boston Scientific Corporation (NYSE:BSX) is a global leader in the manufacture of medical devices, including stents, brain stimulation systems, heart monitors, and catheters. A leading name in robotics, the company has made great strides in the humanoid aspect of the industry with its two-legged Atlas robot. While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
29 minutes ago
- Fox News
WATCH LIVE: Will Cain weighs in on Cracker Barrel's minimalist rebrand
Dr. Ann Shippy also joins the show to discuss America's reproductive health problem and its impact on our youth.
Yahoo
an hour ago
- Yahoo
Medical Device Testing Market Size Attains USD 24.32 Bn by 2034
The global medical device testing market is valued at USD 10.77 billion in 2025 and is projected to grow to approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% during the forecast period. Ottawa, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The global medical device testing market size was valued at USD 9.84 billion in 2024 and is projected to reach approximately USD 24.32 billion by 2034, expanding at a CAGR of 9.47% over the forecast period, according to a study published by Towards Healthcare, a sister firm of Precedence Research. A rise in the need for trustworthy and high-quality medical devices is propelling the expansion of the global market. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways Asia-Pacific led the global medical device testing market in 2024. North America is expected to witness rapid expansion during 2025-2034. By service, the biocompatibility tests segment was dominant in the market in 2024. By service, the chemistry tests segment is expected to register significant growth in the coming years. By phase, the clinical segment held the dominating share of the global medical device testing market in 2024. By phase, the preclinical segment is expected to grow at a notable CAGR during 2025-2034. Market Overview & Potential A process in which the evaluation of the safety, efficiency, and performance of medical devices is conducted, termed medical device testing. Across the globe, the global medical device testing market is experiencing growing regulatory strictness, technological breakthroughs, and a rising healthcare sector. In 2025, it comprises major developments in in-vitro diagnostics (IVD), and the execution of the EU's Medical Device Regulation (MDR) around the market. Usually, it encompasses the evaluation, functionality, durability, sterility, biocompatibility, electrical safety, and usability of the medical device. What are the Key Growth Drivers Involved in The Expansion of The Market? In 2025, several growth factors are impacting the overall development of the global medical device testing market. The growing geriatric population associated with chronic concerns is driving demand for diverse medical devices involved in diabetes management, mobility assistance, and remote patient monitoring. Along with this, an emerging strict regulatory landscape, such as the FDA and the EU's MDR, is offering strong testing guidelines for safety and efficacy. Majorly, different developing medical device producers, particularly startups, are highly outsourcing testing to specialized firms, resulting in market growth. Become a valued research partner with us - What are the Key Drifts Involved in the Market? In August 2025, BDC Laboratories, a leading player in cardiovascular device testing solutions, entered into a strategic partnership with the newly established Dilawri Cardiovascular Institute (DCI) to enhance focus on the development and clinical validation of cardiovascular medical devices. In October 2024, NAMSA, a leader in MedTech Contract Research Organization (CRO) offering end-to-end market access services, and TERUMO, a global player in medical technology, partnered to expand the regulatory approval and commercialization of Terumo's product portfolio. What is the Emerging Challenge in the Market? The need for significant investment in specialized equipment, skilled personnel, and ongoing compliance efforts is creating a major hindrance in the global medical device testing market. Alongside, the widespread requirement for specialized knowledge and skills in areas like biocompatibility, sterilization, and electrical safety is evolving into a barrier to the development of the market. Regional Analysis Why Did Asia Pacific Dominate the Market in 2024? Across the global medical device testing market, the Asia Pacific was dominant in 2024. China, India, and Japan are experiencing a vital expansion due to increasing economies and growing disposable incomes. This ultimately results in a rise in investment in the healthcare system and medical devices, propelling the adoption of various testing services. Additionally, faster advances in different technologies, such as miniaturization, digitalization, and the development of new materials, are enhancing the need for specialized testing March 2025, UL Solutions Inc., a major player in applied safety science, announced its expansion of Songshan Lake IoT Laboratory in Dongguan, China, to support manufacturers in navigating the complexities of connected product and wireless device testing and market access. What Made North America Significantly Grow in the Market in 2024? During 2025-2034, North America is predicted to expand at a rapid CAGR in the global medical device testing market. Merging high R&D investment by many medical device companies, like the adoption of technologies like AI and automation, in this region, is fueling overall market development. Also, North America is focusing on patient safety and regulatory compliance, especially in the US, which requires rigorous testing throughout the product January 2025, Argon Medical Devices enrolled the first patient in a US-based study exploring a newer catheter-based device for managing blood clots in the lungs. In June 2025, Ash, a leading at-home health testing platform, and Impilo, a leader in offering at-home healthcare, partnered to deliver feasible at-home health monitoring and testing nationwide. You can place an order or ask any questions, please feel free to contact us at sales@ Segmental Insights By service analysis Which Service Led the Medical Device Testing Market in 2024? The biocompatibility tests segment held the largest revenue share of the market in 2024. Around the globe, numerous medical device manufacturers are preferring biocompatibility testing to achieve market acceptance and develop a robust reputation for quality and safety. Along with this, these tests are important for reducing the risk of adverse reactions, infections, and other difficulties linked with medical devices. This leads to ensuring patient safety and improving device efficacy. Whereas the chemistry tests segment is predicted to grow rapidly during 2025-2034. Several advantages of this segment are the assessment of the possible toxicity of medical devices and confirming that they will not react negatively with the body. Additionally, the chemistry tests are widely employed in broader devices, from simple disposables to complex implants, to ensure their safety and regulatory compliance. Primarily, they comprise the identification of chemical compounds of a medical device and examination of probable risks linked with their presence, which further assist in biocompatibility assessment. By phase analysis How did the Clinical Segment Hold a Major Share of the Market in 2024? The clinical segment dominated the global medical device testing market in 2024. Usually, different phases of clinical trials offer significant real-world evidence that assists healthcare professionals in making informed decisions about device usage and expands the continuous optimization of medical devices. A surge in 3D printing and AI in medical device manufacturing is boosting the need for clinical trials to study the performance and safety of these new technologies. Also, the segment is driven by the accelerating need for advanced medical devices, a focus on patient safety and efficacy, and a rise in regulatory scrutiny. The preclinical segment is predicted to witness significant expansion in the studied years. Ongoing developments in biocompatibility testing, microbiology testing, and package validation are widely impacting the development of the preclinical phase of the market. Furthermore, various medical device industries, especially small-scale ones, have a shortage of resources or well-trained personnel to execute complete preclinical testing in-house. This further propels the demand for specialized preclinical testing service providers. Whereas, currently growing diverse chronic diseases are fueling demand for enhanced patient safety, which ultimately relies on the development of the preclinical phase. Get the latest insights on healthcare industry segmentation with our Annual Membership: Recent Developments In July 2025, Siemens Healthineers launched the CN-3000 and CN-6000 Hemostasis Systems for coagulation testing in Canada. In May 2025, Roche unveiled the Elecsys PRO-C3 test for the evaluation of the liver fibrosis severity in individuals with signs of metabolic dysfunction–associated steatotic liver disease (MASLD). In March 2025, Nelson Labs launched a groundbreaking rapid sterility testing to notably expedite product sterility results. In October 2024, UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications, introduced FibGel, a natural injectable hydrogel for permanent implantable medical devices. Medical Device Testing Market Key Players SGS SA Laboratory Corporation of America Holdings Nelson Laboratories, LLC TÜV SÜD Charles River Laboratories Element Minnetonka North America Science Associates Inc. (NAMSA) Eurofins Scientific Pace Analytical Services LLC Intertek Group Plc WuXi AppTec Browse More Insights of Towards Healthcare: The global medical device contract manufacturing market is valued at USD 78.61 billion in 2024, expected to grow to USD 87.14 billion in 2025, and projected to reach approximately USD 220.57 billion by 2034, expanding at a CAGR of 10.86% between 2025 and 2034. The global medical device outsourcing market is estimated at USD 160.3 billion in 2024, rising to USD 180.59 billion in 2025, and forecasted to hit nearly USD 507.89 billion by 2034, advancing at a CAGR of 12.65% during 2025–2034. The global pain management devices market stands at USD 7.68 billion in 2024, increasing to USD 8.41 billion in 2025, and is anticipated to reach around USD 19.1 billion by 2034, growing at a CAGR of 9.54% over the forecast period. The global medical device CRO market is valued at USD 8.49 billion in 2024, set to rise to USD 9.25 billion in 2025, and projected to surpass USD 19.9 billion by 2034, at a CAGR of 8.98% between 2025 and 2034. The global wearable medical devices market is calculated at USD 42.78 billion in 2024, climbing to USD 53.68 billion in 2025, and expected to surge to nearly USD 408.61 billion by 2034, registering a strong CAGR of 25.57% from 2025 to 2034. The global implantable medical devices market is estimated at USD 97.17 billion in 2024, growing to USD 103.14 billion in 2025, and forecasted to reach around USD 176.33 billion by 2034, advancing at a CAGR of 6.14% during 2025–2034. The medical device gaskets & seals market was valued at USD 0.92 billion in 2023 and is projected to expand to USD 1.57 billion by 2034, progressing at a CAGR of 5% from 2024 to 2034. The 3D-printed medical devices market is expected to grow from USD 5.59 billion in 2025 to approximately USD 24.69 billion by 2034, witnessing a robust CAGR of 17.94% over the forecast period. The global endoscopy devices market size is valued at USD 61.1 billion in 2024, projected to increase to USD 63.44 billion in 2025, and estimated to reach USD 88.55 billion by 2034, registering a CAGR of 3.82% between 2025 and 2034. The global rehabilitation equipment market is valued at USD 17 billion in 2024, expected to rise to USD 18.42 billion in 2025, and projected to hit USD 37.34 billion by 2034, expanding at a CAGR of 8.34% from 2025 to 2034. Segments Covered in The Report By Service Biocompatibility Tests Cardiovascular Device's Biocompatibility Tests Orthopedic Device's Biocompatibility Tests Dental Implant Devices' Biocompatibility Tests Dermal Filler's Biocompatibility Tests General Surgery Implantation Devices Biocompatibility Tests Neurosurgical Implantation Devices Biocompatibility Tests Ophthalmic Implantation Device's Biocompatibility Tests Others Chemistry Test Chemical characterization (E&L) Analytical method development and validation Toxicological Risk Assessment and consulting Microbiology & Sterility Test Bioburden Determination Pyrogen & Endotoxin Testing Sterility Test & Validation Antimicrobial Testing Others Package Validation By Phase Preclinical Large animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Small animal research Biocompatibility Tests Chemistry Test Microbiology & Sterility Test Clinical By Region North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region: +44 778 256 0738 North America Region: +1 8044 4193 44 APAC Region: +91 9356 9282 04 Web: Our Trusted Data Partners Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | PinterestError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
